TERMS OF USE

Together4Cancer® · NeedleSpotter Inc.

Effective date: April 27, 2026 · Last updated: April 27, 2026

These Terms of Use are divided into two sections:

Section A covers patients and caregivers using together4cancer.com and Before Treatment Starts™.

Section B covers healthcare professionals subscribing to the Together4Cancer® Compass newsletter at together4cancer.org.

Please read the section that applies to you.

For all questions: contact@together4cancer.com

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

SECTION A — PATIENTS AND CAREGIVERS

together4cancer.com · navigator.together4cancer.com · Before Treatment Starts

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

These Terms govern your access to and use of together4cancer.com, navigator.together4cancer.com, Before Treatment Starts™, and future patient-facing products under the Together4Cancer® umbrella operated by NeedleSpotter Inc. By accessing or using our platforms, you agree to be bound by these Terms.

—

A1. ABOUT OUR PATIENT PLATFORMS

Together4Cancer® is a patient education platform operated by NeedleSpotter Inc. Our flagship product, Before Treatment Starts™, is a pre-treatment navigation tool designed to help newly diagnosed cancer patients and their caregivers prepare for conversations with their oncology care team before treatment begins. Additional products may be added under the Together4Cancer® umbrella over time, including ChairSide™ and other patient and caregiver resources. These Terms apply to all current and future Together4Cancer® patient-facing products unless a separate agreement is provided at the time of purchase.

IMPORTANT: All Together4Cancer® patient platforms are educational tools only. They are not medical devices, do not provide medical advice, do not diagnose conditions, and do not recommend specific treatments or medications. All clinical decisions belong to you and your oncology care team. Nothing on these platforms substitutes for the advice of a qualified healthcare professional.

—

A2. ELIGIBILITY AND ACCESS

To use Before Treatment Starts™ or any Together4Cancer® paid product, you must:

· Be at least 18 years of age, or using the platform under the supervision of a parent or legal guardian

· Have purchased a valid access license through our checkout process

· Access the platform using the secure link sent to your registered email address

Your access license is for individual personal use only. Each license grants access to one individual — the person named at checkout. Group use, institutional use, organizational use, and use within coaching programs, support groups, patient navigation services, or any professional practice requires a separate institutional or group license. To inquire about institutional or group licensing, contact contact@together4cancer.com.

Your access license is non-transferable. You may not share your access link with others or allow others to use your account.

—

A3. ACCESS PERIOD

Access periods vary by product and are specified at the time of purchase on the relevant product page. Please review the access terms for the specific Together4Cancer® product you are purchasing before completing your transaction.

Within your access period, you may use the platform as many times as you need. There is no limit on the number of navigation sessions, questions, or documents you generate during your access period.

If you require continued access after your access period expires, please contact us at contact@together4cancer.com to discuss renewal options.

—

A4. REFUND POLICY

Refund policies vary by product and are specified at the time of purchase on the relevant product page. Please review the refund terms for the specific Together4Cancer® product you are purchasing before completing your transaction.

To request a refund for any Together4Cancer® product, email contact@together4cancer.com with your registered email address and the product you purchased. We will respond within 5 business days.

—

A5. NOT MEDICAL ADVICE

All Together4Cancer® patient platforms are educational tools. Explicitly and without limitation:

· We are not a healthcare provider, medical practice, or licensed clinical service

· The content generated by our platforms does not constitute medical advice, diagnosis, or treatment recommendations

· The question scripts and clinical language provided are for educational purposes — to help you have more informed conversations with your care team, not to replace those conversations

· We do not review, validate, or take responsibility for any clinical decisions made in reliance on content generated by our platforms

· You should always consult your oncologist or other qualified healthcare professional before making any treatment decision

If you are experiencing a medical emergency, call 911 or your oncology team’s nurse line immediately. Do not use our platforms in place of emergency medical care.

—

A6. AI-GENERATED CONTENT

Before Treatment Starts™ and other Together4Cancer® tools use artificial intelligence — specifically Anthropic’s Claude — to generate personalized educational content based on information you share. You acknowledge that:

· AI-generated content may contain errors, omissions, or information that does not apply to your specific situation

· All AI-generated content should be reviewed with your healthcare team before acting on it

· Our platforms are grounded in published medical literature and clinical guidelines, but cannot account for all individual clinical variables

· We make no warranty regarding the accuracy, completeness, or applicability of AI-generated content to your specific medical situation

—

A7. APPROPRIATE USE

You agree to use Together4Cancer® patient platforms only for personal educational use in connection with a cancer diagnosis affecting you or someone you are caring for. You agree not to:

· Use any platform for any commercial purpose without our prior written consent

· Attempt to reverse engineer, copy, or reproduce any platform’s AI navigation framework, clinical content, or proprietary methods

· Share your access link with others or allow others to use your account

· Use your individual access license for group, institutional, or organizational purposes without a separate license agreement

· Incorporate platform content or outputs into a coaching program, patient navigation service, professional practice, or any commercial service offering without our prior written consent

· Share, distribute, or reproduce documents generated by the platform — including your Decision Readiness Record™ or Pre-Appointment Patient Brief — for use by anyone other than the individual patient for whom they were generated

· Input false or misleading information with the intent to generate inaccurate clinical content

· Use any platform in any way that violates applicable law or regulation

—

A8. INTELLECTUAL PROPERTY

All content, design, and functionality of Together4Cancer® and its products — including the navigation framework, stage structure, named methods, document formats, and clinical synthesis — is the proprietary intellectual property of NeedleSpotter Inc. and is protected by copyright, trademark, and trade secret law.

Together4Cancer®, Before Treatment Starts™, and ChairSide™ are trademarks of NeedleSpotter Inc. The named methods including Decision Readiness Record™, Pre-Appointment Patient Brief, Testing Completeness™, What Matters To You™, The Decision Layer™, Insider Question Protocol™, Whole Person Data Method™, and Guidance. Grace. Grit.™ are proprietary to NeedleSpotter Inc.

The documents generated for you through our platforms — including your Decision Readiness Record™ and Pre-Appointment Patient Brief — are yours to use for your personal healthcare purposes only.

—

A9. PRIVACY

Your use of Together4Cancer® patient platforms is governed by Section A of our Privacy Policy at together4cancer.com/privacy, which is incorporated into these Terms by reference.

—

A10. DISCLAIMER OF WARRANTIES

Together4Cancer® patient platforms are provided “as is” and “as available” without warranties of any kind. NeedleSpotter Inc. does not warrant that our platforms will be uninterrupted, error-free, or free of harmful components, or that content generated by our platforms will be accurate, complete, or applicable to your specific medical situation.

—

A11. LIMITATION OF LIABILITY

To the fullest extent permitted by applicable law, NeedleSpotter Inc. shall not be liable for any indirect, incidental, special, consequential, or punitive damages arising from your use of any Together4Cancer® patient platform, including any reliance on content generated by our platforms in connection with healthcare decisions. Our total liability to you shall not exceed the amount you paid for your access license.

—

A12. GOVERNING LAW

These Terms are governed by the laws of the State of New Jersey, United States. Any disputes shall be resolved in the courts of New Jersey.

—

A13. CHANGES TO THESE TERMS

We will update the “Last updated” date at the top of this page when we make material changes. Your continued use of our platforms after any changes constitutes your acceptance of the updated Terms.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

SECTION B — HEALTHCARE PROFESSIONALS

together4cancer.org · Together4Cancer® Compass Newsletter

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

These Terms govern your access to and use of together4cancer.org and the Together4Cancer® Compass newsletter, operated by NeedleSpotter Inc. By subscribing to or accessing Compass content, you agree to be bound by these Terms. This section is also relevant to pharmaceutical companies and healthcare organizations considering commercial arrangements with NeedleSpotter Inc. in connection with Compass.

—

B1. ABOUT TOGETHER4CANCER® COMPASS

The Together4Cancer® Compass is a clinician-facing oncology newsletter published by NeedleSpotter Inc. Compass delivers clinical decision gap content, patient communication tools, and actionable oncology guidance to community oncologists, nurse practitioners, and other healthcare professionals.

NeedleSpotter Inc. also operates NeedleSpotter, a B2B oncology marketing agency that partners with pharmaceutical companies on HCP-targeted educational programs. Compass is one channel through which these programs are delivered. Commercial arrangements are structured to maintain editorial independence of non-promotional content, as described in Section B5 below.

IMPORTANT: Compass content is for educational purposes only. It does not constitute clinical guidance, treatment recommendations, or medical advice. All clinical decisions remain the responsibility of the individual clinician and their patient.

—

B2. SUBSCRIPTION AND ACCESS

Compass is a free newsletter delivered by email. By subscribing to Compass — including by not opting out of a subscription invitation — you acknowledge that:

· You are a licensed healthcare professional or work in a clinical or administrative capacity in a healthcare setting

· You consent to receive Compass issues at your professional email address

· You have read and agree to these Terms and the Compass Privacy Policy at together4cancer.com/privacy

· You understand that Compass may deliver both non-promotional educational content and clearly marked promotional communications on behalf of pharmaceutical company partners

You may unsubscribe from Compass at any time by clicking the unsubscribe link in any issue or by emailing contact@together4cancer.com.

—

B3. CONTENT — NON-PROMOTIONAL AND PROMOTIONAL

Non-promotional content

The majority of Compass content is non-promotional editorial content produced independently by NeedleSpotter Inc., including clinical decision gap analyses, patient communication scripts, disease state updates, and clinical tool recommendations. Non-promotional content may be supported by unrestricted educational grants from pharmaceutical companies. Sponsors of non-promotional content do not participate in its creation, review, or approval.

Promotional content

Compass may deliver MLR-reviewed promotional email communications on behalf of pharmaceutical company partners. All promotional communications will be:

· Clearly marked as PROMOTIONAL at the top of the email

· Identified by the name of the sponsoring pharmaceutical company

· Compliant with applicable FDA promotional guidelines and PhRMA codes of conduct

Promotional communications are delivered as separate, clearly marked emails. Subscribers may opt out of promotional communications while remaining subscribed to non-promotional Compass content by emailing contact@together4cancer.com with the subject line “Opt out of promotional emails.”

—

B4. EDITORIAL INDEPENDENCE AND SPONSORED CONTENT DISCLOSURE

NeedleSpotter Inc. maintains full editorial independence over all non-promotional Compass content. Commercial arrangements of any kind — including unrestricted educational grants, NPI-matched reporting, sponsored tracking, MLR-reviewed promotional programs, sponsored content series, disease awareness campaigns, patient education initiatives, branded and unbranded HCP communications, and any other pharmaceutical or healthcare industry partnership — do not influence the editorial content, clinical positions, or therapy references in non-promotional Compass issues. Sponsors do not review, approve, or modify non-promotional editorial content prior to publication.

All sponsored, promotional, or commercially supported content will be explicitly identified at the point of delivery. Identification will include one or more of the following disclosures as appropriate to the content type:

· “Promotional” — for MLR-reviewed branded promotional communications · “Sponsored by [Company Name]” — for branded sponsored content series or disease awareness campaigns · “Supported by an unrestricted educational grant from [Company Name]” — for grant-funded non-promotional content · “This communication includes reach measurement tools provided by an educational grant supporter” — for issues containing sponsor tracking tags or pixels · Any other disclosure required by applicable FDA guidelines, PhRMA codes of conduct, or industry standards

NeedleSpotter Inc. reserves the right to enter into any lawful pharmaceutical or healthcare industry commercial arrangement in connection with Compass, provided that non-promotional editorial independence is maintained and all commercial relationships are disclosed to subscribers at the point of delivery.

This editorial independence policy is a condition of all commercial arrangements entered into by NeedleSpotter Inc. in connection with Compass.

—

B5. EDITORIAL INDEPENDENCE

NeedleSpotter Inc. maintains full editorial independence over all non-promotional Compass content. Commercial arrangements of any kind do not influence the editorial content, clinical positions, or therapy references in non-promotional Compass issues. Sponsors do not review, approve, or modify non-promotional editorial content prior to publication. This editorial independence is a condition of all commercial arrangements entered into by NeedleSpotter Inc. in connection with Compass.

—

B6. PHARMACEUTICAL COMPANY PARTNERS — SPECIFIC ACKNOWLEDGMENTS

If you are accessing these Terms on behalf of a pharmaceutical company or healthcare organization considering a commercial arrangement with NeedleSpotter Inc. in connection with Compass, you acknowledge that:

· NPI-matched engagement reporting does not involve the transfer of subscriber personal information to the partner

· Sponsored tracking tags collect engagement metrics only and are disclosed to subscribers

· MLR-reviewed promotional communications are delivered as clearly marked separate communications in compliance with applicable FDA and PhRMA guidelines

· Unrestricted educational grant arrangements require full editorial independence as a condition of the arrangement

· All commercial arrangements are governed by a separate written agreement between NeedleSpotter Inc. and the partner organization

To discuss commercial arrangements: contact@together4cancer.com

—

B7. INTELLECTUAL PROPERTY

All Compass content — including clinical analyses, patient communication scripts, decision gap frameworks, and editorial content — is the proprietary intellectual property of NeedleSpotter Inc. and is protected by copyright law.

You may share individual Compass issues with colleagues for personal educational purposes. You may not:

· Reproduce, republish, or distribute Compass content in any commercial context without our prior written consent

· Incorporate Compass content into any product, service, training program, or commercial offering without a license agreement

· Remove or obscure any attribution, copyright notice, or branding from Compass content

To inquire about licensing Compass content for institutional or commercial use, contact contact@together4cancer.com.

—

B8. DISCLAIMERS

Compass content is produced to high clinical standards and is grounded in published medical literature and clinical guidelines. However, NeedleSpotter Inc. makes no warranty regarding the completeness, accuracy, or applicability of Compass content to any specific clinical situation. Compass content reflects the state of published evidence at the time of publication and may not reflect subsequent developments. NeedleSpotter Inc. is not responsible for clinical decisions made in reliance on Compass content.

—

B9. LIMITATION OF LIABILITY

To the fullest extent permitted by applicable law, NeedleSpotter Inc. shall not be liable for any indirect, incidental, special, consequential, or punitive damages arising from your use of or reliance on Compass content, including any clinical decisions made in connection with that content.

—

B10. GOVERNING LAW

These Terms are governed by the laws of the State of New Jersey, United States. Any disputes shall be resolved in the courts of New Jersey.

—

B11. CHANGES TO THESE TERMS

When we make material changes to Section B — particularly changes affecting commercial arrangements or subscriber data practices — we will notify subscribers by email before those changes take effect.

—

CONTACT US

NeedleSpotter Inc.

Operating as Together4Cancer® · NeedleSpotter

New Jersey, USA

contact@together4cancer.com

We respond to all inquiries within 5 business days.

—

© 2026 NeedleSpotter Inc. · Together4Cancer®

together4cancer.com/terms